MeSH term
Frequency | Condition_Probility | Female | 49 | 0.0 |
Humans | 327 | 0.0 |
Pregnancy | 5 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Albumins/metabolism | 2 | 1.0 |
Albuminuria/*prevention & control | 2 | 2.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 2 | 2.0 |
Hypertension/complications/*drug therapy | 2 | 1.0 |
Indoles/*therapeutic use | 2 | 1.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Binding Sites/genetics | 5 | 0.0 |
DNA Mutational Analysis | 9 | 0.0 |
DNA, Neoplasm/chemistry/genetics | 2 | 1.0 |
Databases | 2 | 2.0 |
Family Health | 2 | 0.0 |
*Germ-Line Mutation | 2 | 0.0 |
Phenotype | 6 | 0.0 |
*Proto-Oncogene Proteins | 7 | 0.0 |
Research Support, Non-U.S. Gov't | 254 | 0.0 |
Amino Acid Motifs | 9 | 1.0 |
Animals | 182 | 0.0 |
Base Sequence | 43 | 0.0 |
Binding Sites | 35 | 0.0 |
Binding, Competitive | 5 | 0.0 |
Blotting, Northern | 19 | 0.0 |
Blotting, Western | 31 | 0.0 |
COS Cells | 54 | 1.0 |
Cell Differentiation | 12 | 0.0 |
Cell Nucleus/metabolism | 26 | 1.0 |
Cells, Cultured | 46 | 0.0 |
DNA/*metabolism | 5 | 1.0 |
DNA-Binding Proteins/*metabolism | 70 | 3.0 |
Drosophila | 2 | 0.0 |
Fibroblasts/metabolism | 7 | 0.0 |
Genes, Reporter | 39 | 1.0 |
Immunoblotting | 17 | 0.0 |
Mice | 75 | 0.0 |
Molecular Sequence Data | 56 | 0.0 |
Muscle, Smooth/*metabolism | 2 | 8.0 |
Mutation | 23 | 0.0 |
Oligonucleotides/metabolism | 2 | 2.0 |
Plasmids/metabolism | 25 | 2.0 |
Plicamycin/*analogs & derivatives/pharmacology | 2 | 28.0 |
Protein Binding | 68 | 0.0 |
Rats | 29 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 132 | 0.0 |
Transcription Factor, Sp1/*metabolism | 5 | 1.0 |
Transcription Factors/*metabolism | 12 | 0.0 |
*Transcription, Genetic | 9 | 0.0 |
Transfection | 88 | 0.0 |
Transforming Growth Factor beta/metabolism | 19 | 9.0 |
Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated/etiology | 2 | 66.0 |
Nuclear Proteins/metabolism | 14 | 1.0 |
Signal Transduction | 85 | 1.0 |
Transforming Growth Factor beta/*antagonists & inhibitors/physiology | 3 | 60.0 |
Cell Division | 21 | 0.0 |
Cell Line | 102 | 0.0 |
*Signal Transduction | 41 | 2.0 |
Transforming Growth Factor beta/*physiology | 21 | 16.0 |
Cytoskeletal Proteins/metabolism | 3 | 1.0 |
DNA-Binding Proteins/*genetics | 17 | 0.0 |
Loss of Heterozygosity | 4 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Mice, Knockout | 11 | 0.0 |
Trans-Activators/*genetics | 15 | 4.0 |
Male | 33 | 0.0 |
Choriocarcinoma/genetics/*metabolism | 2 | 100.0 |
DNA-Binding Proteins/genetics/*metabolism | 30 | 3.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Trans-Activation (Genetics) | 26 | 1.0 |
Trans-Activators/genetics/*metabolism | 29 | 7.0 |
Transforming Growth Factor beta/*pharmacology | 52 | 13.0 |
Tumor Cells, Cultured | 68 | 0.0 |
Activin Receptors, Type I/metabolism | 4 | 22.0 |
Imidazoles/pharmacology | 4 | 1.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors | 3 | 5.0 |
Pyridines/pharmacology | 4 | 1.0 |
RNA, Messenger/drug effects/metabolism | 2 | 1.0 |
Receptors, Transforming Growth Factor beta/metabolism | 14 | 32.0 |
Transforming Growth Factor beta/*antagonists & inhibitors | 6 | 46.0 |
p38 Mitogen-Activated Protein Kinases | 7 | 1.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
Cattle | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 32 | 1.0 |
Protein Conformation | 8 | 0.0 |
Protein Folding | 3 | 0.0 |
Protein Kinases/metabolism | 4 | 0.0 |
Protein-Serine-Threonine Kinases/metabolism | 7 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 8 | 0.0 |
Trans-Activators/metabolism | 34 | 3.0 |
Luciferases/genetics/metabolism | 3 | 1.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Recombinant Fusion Proteins/metabolism | 14 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 34 | 0.0 |
Cell Movement/physiology | 3 | 1.0 |
Phosphorylation | 62 | 0.0 |
Signal Transduction/*physiology | 26 | 2.0 |
Wound Healing/*physiology | 3 | 4.0 |
p38 Mitogen-Activated Protein Kinases/metabolism | 2 | 6.0 |
Adolescent | 7 | 0.0 |
Adult | 22 | 0.0 |
Aged | 10 | 0.0 |
Comparative Study | 14 | 0.0 |
Immunohistochemistry | 10 | 0.0 |
Middle Aged | 16 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 3 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Enzyme Activation | 7 | 0.0 |
Glutathione Transferase/metabolism | 9 | 1.0 |
Precipitin Tests | 27 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 10 | 0.0 |
Trans-Activators/*metabolism | 74 | 7.0 |
Transcription Factor AP-1/metabolism | 7 | 2.0 |
DNA Primers | 10 | 0.0 |
*Trans-Activation (Genetics) | 11 | 1.0 |
Two-Hybrid System Techniques | 13 | 1.0 |
Activin Receptors, Type II/genetics/metabolism | 2 | 100.0 |
Activins/pharmacology | 4 | 40.0 |
Amino Acid Sequence | 32 | 0.0 |
CHO Cells | 5 | 0.0 |
Cloning, Molecular | 15 | 0.0 |
Gene Expression | 13 | 0.0 |
Hamsters | 5 | 0.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Protein Binding/physiology | 3 | 1.0 |
*Proteins | 3 | 0.0 |
Signal Transduction/drug effects/physiology | 4 | 1.0 |
Structure-Activity Relationship | 4 | 0.0 |
Cell Division/drug effects/genetics | 3 | 3.0 |
DNA-Binding Proteins/*genetics/metabolism | 9 | 2.0 |
Exons | 5 | 0.0 |
Genes, Dominant | 7 | 0.0 |
*Mutation | 7 | 0.0 |
Signal Transduction/genetics/physiology | 2 | 4.0 |
Trans-Activators/*genetics/metabolism | 8 | 7.0 |
Transforming Growth Factor beta/*pharmacology/physiology | 2 | 18.0 |
*Gene Expression | 2 | 0.0 |
Inhibin-beta Subunits/pharmacology | 3 | 42.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Transforming Growth Factor beta/pharmacology | 12 | 3.0 |
DNA-Binding Proteins/biosynthesis/genetics | 2 | 2.0 |
Enzyme-Linked Immunosorbent Assay | 7 | 0.0 |
Receptors, Transforming Growth Factor beta/biosynthesis/genetics | 2 | 40.0 |
Signal Transduction/physiology | 21 | 2.0 |
Trans-Activators/biosynthesis/genetics | 3 | 8.0 |
Activins/metabolism | 3 | 42.0 |
Helix-Loop-Helix Motifs | 2 | 0.0 |
Ligands | 16 | 0.0 |
Models, Biological | 15 | 0.0 |
Promoter Regions (Genetics) | 50 | 1.0 |
Protein Structure, Tertiary | 34 | 0.0 |
Sequence Homology, Amino Acid | 12 | 0.0 |
Transcription, Genetic | 47 | 0.0 |
Xenopus | 6 | 1.0 |
Activin Receptors, Type I/*metabolism | 2 | 25.0 |
Activins/*metabolism/pharmacology | 2 | 66.0 |
*Apoptosis | 5 | 0.0 |
Cercopithecus aethiops | 9 | 0.0 |
Jurkat Cells | 4 | 0.0 |
Phosphoproteins/genetics/*metabolism | 3 | 1.0 |
Up-Regulation | 9 | 0.0 |
ras Proteins/metabolism | 2 | 1.0 |
Phosphorylation/drug effects | 6 | 0.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Signal Transduction/drug effects | 10 | 1.0 |
Transcription, Genetic/drug effects | 11 | 1.0 |
Time Factors | 29 | 0.0 |
Osteoblasts/cytology/drug effects/*metabolism | 2 | 16.0 |
Receptors, Transforming Growth Factor beta/genetics/metabolism | 4 | 26.0 |
*Transforming Growth Factor beta | 2 | 1.0 |
ras Proteins/*metabolism | 3 | 1.0 |
Cell Cycle Proteins/*genetics/metabolism | 2 | 3.0 |
*Tumor Suppressor Proteins | 3 | 0.0 |
DNA-Binding Proteins/*physiology | 10 | 1.0 |
Transcription Factors/*physiology | 4 | 0.0 |
Interleukin-10/biosynthesis | 2 | 1.0 |
Macromolecular Substances | 13 | 0.0 |
DNA-Binding Proteins/physiology | 6 | 2.0 |
Trans-Activators/physiology | 8 | 5.0 |
Transforming Growth Factor beta/metabolism/*physiology | 2 | 33.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
DNA, Complementary/metabolism | 11 | 0.0 |
Dose-Response Relationship, Drug | 20 | 0.0 |
Recombinant Proteins/metabolism | 13 | 0.0 |
Transforming Growth Factor beta/*metabolism | 71 | 31.0 |
Adenoviridae/genetics | 2 | 0.0 |
Apoptosis | 4 | 0.0 |
DNA-Binding Proteins/*biosynthesis/genetics | 5 | 5.0 |
Hela Cells | 8 | 0.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Luciferases/metabolism | 18 | 2.0 |
Mitogen-Activated Protein Kinases/metabolism | 6 | 0.0 |
RNA, Messenger/metabolism | 21 | 0.0 |
Sequence Analysis, DNA | 6 | 0.0 |
Trans-Activators/*biosynthesis/genetics | 5 | 17.0 |
Transforming Growth Factor beta/*antagonists & inhibitors/metabolism | 2 | 40.0 |
Cell Cycle/physiology | 4 | 1.0 |
Fungal Proteins/metabolism | 2 | 1.0 |
Ligases/*metabolism | 3 | 3.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 3 | 0.0 |
*Saccharomyces cerevisiae Proteins | 4 | 0.0 |
Sequence Alignment | 7 | 0.0 |
Transcription Factors/metabolism | 14 | 0.0 |
*Ubiquitin-Protein Ligase Complexes | 2 | 2.0 |
Ubiquitin-Protein Ligases | 5 | 2.0 |
Xenopus laevis | 4 | 0.0 |
Trans-Activators/*physiology | 10 | 3.0 |
Apoptosis/drug effects | 2 | 0.0 |
Cell Division/drug effects | 14 | 0.0 |
Cell Line, Tumor | 20 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 6 | 1.0 |
Fibroblasts | 2 | 0.0 |
Mutation/genetics | 5 | 0.0 |
Protein Transport | 6 | 0.0 |
Signal Transduction/*drug effects | 4 | 1.0 |
Trans-Activators/genetics/metabolism | 7 | 4.0 |
Cystic Fibrosis/*metabolism/pathology | 2 | 25.0 |
Enzyme Induction | 2 | 0.0 |
Gene Expression Regulation | 21 | 0.0 |
Inflammation | 2 | 0.0 |
Liver/metabolism | 3 | 0.0 |
Luciferases/biosynthesis/genetics | 2 | 3.0 |
NF-kappa B/metabolism | 3 | 0.0 |
Organ Specificity | 2 | 0.0 |
Adenocarcinoma | 2 | 1.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Immediate-Early Proteins/metabolism | 2 | 6.0 |
Prostatic Neoplasms | 3 | 5.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Receptors, Androgen/genetics/*metabolism | 2 | 4.0 |
DNA-Binding Proteins/*chemistry/*metabolism | 2 | 3.0 |
Gene Deletion | 9 | 0.0 |
Models, Genetic | 9 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 9 | 0.0 |
Retroviridae/genetics | 3 | 0.0 |
Trans-Activators/*chemistry/*metabolism | 2 | 11.0 |
Ubiquitin/*metabolism | 4 | 2.0 |
*Cell Cycle Proteins | 4 | 0.0 |
*Promoter Regions (Genetics) | 14 | 0.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
*Gene Expression Regulation | 12 | 0.0 |
Nuclear Proteins | 2 | 4.0 |
DNA-Binding Proteins/genetics/metabolism/*physiology | 2 | 3.0 |
*Proto-Oncogenes | 5 | 0.0 |
Transforming Growth Factor beta/physiology | 9 | 9.0 |
Activins | 11 | 15.0 |
Consensus Sequence | 4 | 0.0 |
Inhibins/metabolism | 2 | 13.0 |
Response Elements | 5 | 2.0 |
Carcinoma, Hepatocellular | 4 | 1.0 |
Gene Expression Regulation/*drug effects | 6 | 0.0 |
Liver Neoplasms | 4 | 1.0 |
Luciferases/genetics | 6 | 1.0 |
Protein Biosynthesis | 2 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 3 | 0.0 |
Plasmids/genetics | 2 | 0.0 |
Polymerase Chain Reaction | 9 | 0.0 |
Transforming Growth Factor beta/*metabolism/pharmacology | 7 | 28.0 |
Fibroblasts/*metabolism | 2 | 1.0 |
Genetic Vectors | 8 | 0.0 |
*Transcription Factors | 4 | 0.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
*Activin Receptors, Type I | 7 | 28.0 |
Gene Expression/drug effects | 3 | 0.0 |
Protein-Serine-Threonine Kinases/biosynthesis | 2 | 6.0 |
Receptors, Calcitriol/metabolism | 2 | 3.0 |
Thymidine/metabolism | 4 | 1.0 |
Cytoplasm/metabolism | 7 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Microscopy, Fluorescence | 7 | 0.0 |
Phosphoproteins/metabolism | 3 | 0.0 |
*Repressor Proteins | 3 | 0.0 |
*Zebrafish Proteins | 3 | 1.0 |
DNA/metabolism | 16 | 1.0 |
Fibroblasts/cytology | 3 | 1.0 |
Promoter Regions (Genetics)/*drug effects | 2 | 4.0 |
Proto-Oncogene Proteins c-jun/metabolism | 3 | 2.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Substrate Specificity | 3 | 0.0 |
Transcription Factor AP-1/*metabolism | 3 | 1.0 |
Transcription, Genetic/*drug effects | 5 | 1.0 |
DNA-Binding Proteins/*biosynthesis | 4 | 3.0 |
Ribonucleases/metabolism | 2 | 1.0 |
Trans-Activators/*biosynthesis | 4 | 7.0 |
DNA/genetics/metabolism | 3 | 0.0 |
Trans-Activation (Genetics)/*physiology | 4 | 3.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Mink | 15 | 23.0 |
Ubiquitins/metabolism | 2 | 1.0 |
Receptors, Transforming Growth Factor beta/*physiology | 3 | 30.0 |
Transforming Growth Factor beta/pharmacology/*physiology | 3 | 12.0 |
Mice, Inbred BALB C | 4 | 0.0 |
Cell Division/physiology | 6 | 0.0 |
Mitogen-Activated Protein Kinases/physiology | 3 | 2.0 |
Cell Line, Transformed | 4 | 0.0 |
Cell Transformation, Neoplastic | 4 | 0.0 |
Gene Expression Regulation/drug effects | 8 | 0.0 |
Genes, Tumor Suppressor | 8 | 0.0 |
Isopropyl Thiogalactoside/pharmacology | 2 | 11.0 |
Kinetics | 6 | 0.0 |
Signal Transduction/drug effects/*physiology | 3 | 1.0 |
Cysteine Endopeptidases/metabolism | 2 | 0.0 |
Genes, Reporter/genetics | 2 | 0.0 |
Multienzyme Complexes/metabolism | 2 | 1.0 |
Proteasome Endopeptidase Complex | 4 | 0.0 |
Cell Differentiation/drug effects | 6 | 0.0 |
Trans-Activation (Genetics)/drug effects | 4 | 1.0 |
Inhibins/pharmacology | 2 | 11.0 |
Trans-Activation (Genetics)/*drug effects | 3 | 3.0 |
Adenocarcinoma/pathology | 2 | 2.0 |
Gene Expression Regulation, Neoplastic | 8 | 0.0 |
*Genes, Tumor Suppressor | 3 | 0.0 |
Transforming Growth Factor beta/*genetics | 4 | 4.0 |
Repressor Proteins/genetics/metabolism | 4 | 4.0 |
Transforming Growth Factor beta/genetics/*metabolism | 7 | 18.0 |
Transcription, Genetic/physiology | 5 | 2.0 |
Active Transport, Cell Nucleus | 7 | 2.0 |
Cell Nucleus/*metabolism | 4 | 0.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
Haplorhini | 2 | 0.0 |
Receptor Cross-Talk/*physiology | 2 | 15.0 |
Trans-Activation (Genetics)/physiology | 5 | 5.0 |
Transcription, Genetic/*physiology | 7 | 3.0 |
Collagen/*genetics | 2 | 0.0 |
Fibroblasts/cytology/*metabolism | 3 | 8.0 |
Skin/cytology/*metabolism | 2 | 5.0 |
Drug Synergism | 4 | 0.0 |
Mutagenesis | 4 | 0.0 |
Sequence Deletion | 3 | 0.0 |
3T3 Cells | 9 | 0.0 |
Actins/*biosynthesis | 2 | 22.0 |
Active Transport, Cell Nucleus/drug effects | 2 | 5.0 |
DNA-Binding Proteins/*metabolism/physiology | 6 | 15.0 |
Trans-Activators/*metabolism/physiology | 4 | 25.0 |
Gene Expression Regulation/*physiology | 5 | 1.0 |
Child | 3 | 0.0 |
T-Lymphocytes/*metabolism | 2 | 0.0 |
Oligonucleotides, Antisense/chemistry | 3 | 13.0 |
RNA Interference | 2 | 0.0 |
RNA, Small Interfering/metabolism | 7 | 3.0 |
DNA-Binding Proteins/*chemistry/metabolism | 3 | 4.0 |
Models, Molecular | 6 | 0.0 |
Trans-Activators/*chemistry/metabolism | 3 | 20.0 |
Crystallography, X-Ray | 3 | 0.0 |
DNA-Binding Proteins/*chemistry/genetics/*metabolism | 2 | 3.0 |
Enzyme Activation/drug effects | 4 | 0.0 |
Trans-Activators/*chemistry/genetics/*metabolism | 2 | 9.0 |
Growth Inhibitors/*pharmacology | 3 | 1.0 |
Peptide Fragments/chemistry/genetics/metabolism | 2 | 2.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
Cysteine Proteinase Inhibitors/pharmacology | 2 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
DNA-Binding Proteins/*genetics/*physiology | 2 | 5.0 |
Trans-Activators/*genetics/*physiology | 2 | 16.0 |
Fibroblasts/*metabolism/pathology | 2 | 8.0 |
Scleroderma, Systemic/*metabolism/pathology | 2 | 33.0 |
Drug Antagonism | 2 | 4.0 |
Interferon Type II/*pharmacology | 2 | 0.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
DNA-Binding Proteins/chemistry/*metabolism | 4 | 2.0 |
Trans-Activators/chemistry/*metabolism | 5 | 7.0 |
Collagen/*biosynthesis | 2 | 5.0 |
Aged, 80 and over | 6 | 0.0 |
Melanoma/genetics/*metabolism | 2 | 12.0 |
*Active Transport, Cell Nucleus | 3 | 7.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
*Xenopus Proteins | 14 | 3.0 |
Plasminogen Activator Inhibitor 1/biosynthesis/*genetics | 2 | 33.0 |
DNA-Binding Proteins/analysis/*genetics/metabolism | 2 | 25.0 |
Epithelial Cells/metabolism | 3 | 0.0 |
Lung | 3 | 3.0 |
Trans-Activators/analysis/*genetics/metabolism | 2 | 66.0 |
Biological Transport | 3 | 0.0 |
*Mutation, Missense | 2 | 0.0 |
DNA-Binding Proteins/genetics | 8 | 0.0 |
Polymorphism, Genetic | 5 | 0.0 |
Polymorphism, Single-Stranded Conformational | 6 | 0.0 |
Receptors, Transforming Growth Factor beta/genetics | 3 | 5.0 |
Trans-Activators/genetics | 9 | 4.0 |
Cell Transformation, Neoplastic/*metabolism | 2 | 5.0 |
Disease Models, Animal | 5 | 0.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Lung/*metabolism | 2 | 2.0 |
Nuclear Proteins/genetics/*metabolism | 3 | 0.0 |
Transcription Factors/genetics/*metabolism | 8 | 1.0 |
Cytokines/metabolism | 2 | 0.0 |
Actins/metabolism | 3 | 0.0 |
Epithelial Cells/cytology | 2 | 2.0 |
Mice, Transgenic | 3 | 0.0 |
Apoptosis/*drug effects | 2 | 0.0 |
*Proto-Oncogene Proteins c-fos | 2 | 28.0 |
Response Elements/genetics | 2 | 1.0 |
DNA-Binding Proteins/chemistry/*physiology | 2 | 6.0 |
Trans-Activators/chemistry/*physiology | 2 | 11.0 |
Fibroblasts/cytology/metabolism | 5 | 2.0 |
RNA, Messenger | 2 | 0.0 |
Receptors, Cytoplasmic and Nuclear/metabolism | 2 | 1.0 |
Skin/cytology | 2 | 1.0 |
Homeodomain Proteins/genetics/metabolism | 2 | 2.0 |
Cyclins/genetics/*metabolism | 2 | 2.0 |
Keratinocytes/*metabolism | 5 | 5.0 |
DNA-Binding Proteins/*antagonists & inhibitors/physiology | 2 | 66.0 |
MAP Kinase Kinase 1 | 2 | 1.0 |
*MAP Kinase Kinase 4 | 4 | 7.0 |
Trans-Activators/*antagonists & inhibitors/physiology | 2 | 33.0 |
Cell Movement | 2 | 0.0 |
Dimerization | 5 | 0.0 |
Wound Healing | 3 | 2.0 |
Antigens, CD95/metabolism | 2 | 1.0 |
Protein Isoforms | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 10 | 0.0 |
Flavonoids/pharmacology | 3 | 0.0 |
MAP Kinase Signaling System | 2 | 0.0 |
Cell Cycle | 4 | 0.0 |
Flow Cytometry | 8 | 0.0 |
*MAP Kinase Signaling System | 3 | 2.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 4 | 0.0 |
Genes, Regulator/genetics | 2 | 4.0 |
Receptors, Growth Factor/metabolism | 3 | 2.0 |
Transforming Growth Factor beta/antagonists & inhibitors/physiology | 2 | 66.0 |
Trans-Activators/drug effects/genetics/*metabolism | 2 | 16.0 |
Transforming Growth Factor beta/metabolism/pharmacology | 2 | 22.0 |
Gene Expression Regulation, Developmental | 4 | 0.0 |
Transforming Growth Factor beta/genetics/metabolism | 6 | 17.0 |
JNK Mitogen-Activated Protein Kinases | 3 | 0.0 |
*MAP Kinase Kinase Kinase 1 | 2 | 1.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
*Mitogen-Activated Protein Kinase Kinases | 2 | 2.0 |
Cyclins/*genetics | 2 | 1.0 |
Receptors, Transforming Growth Factor beta/physiology | 3 | 30.0 |
Transcription Factor, Sp1/metabolism | 2 | 0.0 |
*Protein-Serine-Threonine Kinases | 3 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 2 | 0.0 |
Acetyltransferases/metabolism | 2 | 2.0 |
DNA-Binding Proteins/*genetics/*metabolism | 4 | 2.0 |
Histone Deacetylases/metabolism | 3 | 3.0 |
Proto-Oncogene Proteins/*genetics/*metabolism | 2 | 4.0 |
Astrocytes/cytology/drug effects/*metabolism | 2 | 15.0 |
Blotting, Southern | 2 | 0.0 |
*CDC2-CDC28 Kinases | 2 | 0.0 |
Carrier Proteins/*metabolism | 4 | 0.0 |
Cyclin-Dependent Kinases/metabolism | 3 | 0.0 |
Cyclins/metabolism | 3 | 0.0 |
G1 Phase/drug effects | 2 | 1.0 |
Glioma/*metabolism/pathology | 2 | 7.0 |
*Protein p16 | 2 | 5.0 |
Plasminogen Activator Inhibitor 1/*genetics | 6 | 17.0 |
*Nuclear Proteins | 3 | 0.0 |
Rabbits | 2 | 0.0 |
Plasminogen Activator Inhibitor 1/genetics | 4 | 12.0 |
Activin Receptors | 3 | 16.0 |
Inhibins/*pharmacology | 2 | 18.0 |
Repressor Proteins/metabolism | 3 | 1.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Collagen/genetics | 2 | 2.0 |
Glomerular Mesangium/cytology/*physiology | 2 | 22.0 |
Promoter Regions (Genetics)/physiology | 4 | 2.0 |
RNA, Messenger/analysis | 9 | 0.0 |
Signal Transduction/*drug effects/physiology | 2 | 3.0 |
Transforming Growth Factor beta/metabolism/*pharmacology | 2 | 18.0 |
Mice, Nude | 3 | 0.0 |
Embryo, Nonmammalian/metabolism | 3 | 7.0 |
Gene Expression Regulation, Developmental/*physiology | 2 | 1.0 |
Xenopus/embryology | 2 | 15.0 |
Adenomatous Polyposis Coli/*genetics | 2 | 3.0 |
Genetic Markers | 2 | 0.0 |
Phosphoproteins/genetics | 2 | 1.0 |
Transforming Growth Factor beta/genetics | 2 | 2.0 |
Disease Progression | 4 | 0.0 |
Protein Processing, Post-Translational | 5 | 0.0 |
Transforming Growth Factor beta/antagonists & inhibitors/*metabolism | 3 | 30.0 |
Point Mutation | 5 | 0.0 |
Chromosomes, Human, Pair 21 | 2 | 1.0 |
Chromosomes, Human, Pair 3 | 2 | 1.0 |
Receptors, Transforming Growth Factor beta/*genetics | 3 | 6.0 |
Epithelial Cells/*metabolism | 2 | 1.0 |
Receptors, Transforming Growth Factor beta/*metabolism | 5 | 18.0 |
DNA/genetics | 2 | 0.0 |
Down-Regulation | 7 | 0.0 |
Fibrosis | 5 | 3.0 |
Trans-Activators/*genetics/*metabolism | 2 | 5.0 |
Protein-Serine-Threonine Kinases/*metabolism | 3 | 0.0 |
DNA-Binding Proteins/biosynthesis/*genetics | 2 | 1.0 |
Signal Transduction/genetics | 5 | 1.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 11 | 1.0 |
*Serine Endopeptidases | 4 | 11.0 |
Subcellular Fractions | 3 | 1.0 |
Myocytes, Smooth Muscle/*metabolism | 2 | 33.0 |
Adenovirus E1A Proteins/metabolism | 2 | 6.0 |
DNA-Binding Proteins/chemistry/genetics/*metabolism | 6 | 3.0 |
Trans-Activators/chemistry/genetics/*metabolism | 5 | 6.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Cell Survival | 2 | 0.0 |
Epithelial Cells/*cytology/metabolism | 2 | 12.0 |
Transforming Growth Factor beta/genetics/*metabolism/pharmacology | 2 | 66.0 |
Antibody Specificity | 2 | 0.0 |
Leucine Zippers | 2 | 1.0 |
Cell Division/genetics | 2 | 0.0 |
Mice, Mutant Strains | 2 | 0.0 |
DNA-Binding Proteins/antagonists & inhibitors/*metabolism | 2 | 7.0 |
Trans-Activators/antagonists & inhibitors/*metabolism | 2 | 8.0 |
Chromones/pharmacology | 2 | 0.0 |
Collagen Type I/*genetics | 2 | 9.0 |
Morpholines/pharmacology | 2 | 0.0 |
Scleroderma, Diffuse/*metabolism | 2 | 100.0 |
*Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Alkaline Phosphatase/metabolism | 3 | 2.0 |
Bone Morphogenetic Proteins/*metabolism | 4 | 9.0 |
Neoplasm Proteins/*metabolism | 4 | 0.0 |
RNA/metabolism | 7 | 1.0 |
1-Phosphatidylinositol 3-Kinase/genetics | 2 | 16.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 2 | 1.0 |
Mitochondrial Proteins/genetics | 2 | 15.0 |
Signal Transduction/*genetics | 3 | 2.0 |
Neoplasm Invasiveness | 2 | 0.0 |
*Trans-Activators | 7 | 1.0 |
Trans-Activation (Genetics)/*genetics | 2 | 2.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Mesoderm/physiology | 3 | 8.0 |
Protein-Serine-Threonine Kinases/genetics/metabolism | 2 | 1.0 |
Chromatin/metabolism | 2 | 0.0 |
Colorectal Neoplasms/*genetics | 2 | 0.0 |
*Gene Silencing | 2 | 1.0 |
Adenoviridae/genetics/metabolism | 2 | 6.0 |
Cytochromes c/metabolism | 2 | 3.0 |
Activins/genetics/*metabolism | 2 | 100.0 |
In Vitro | 3 | 0.0 |
Collagen/genetics/metabolism | 3 | 20.0 |
Actins/genetics | 2 | 1.0 |
Infant, Newborn | 2 | 0.0 |
Altruism | 2 | 6.0 |
Cell Proliferation/drug effects | 3 | 3.0 |
Fibroblasts/*physiology | 2 | 3.0 |
Gene Expression Profiling | 5 | 0.0 |
Oligonucleotide Array Sequence Analysis | 6 | 0.0 |
Fibroblasts/drug effects/metabolism | 2 | 1.0 |
Gene Silencing | 2 | 0.0 |
Ubiquitin/metabolism | 2 | 0.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Protein Transport/drug effects | 2 | 3.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Mutation, Missense/genetics | 2 | 1.0 |
Drug Interactions | 3 | 0.0 |
Receptors, Transforming Growth Factor beta/*antagonists & inhibitors | 2 | 50.0 |
Enhancer Elements (Genetics) | 2 | 0.0 |
Amino Acid Substitution | 3 | 0.0 |
Immunoprecipitation | 2 | 0.0 |
Carrier Proteins/chemistry/genetics/*metabolism | 3 | 2.0 |
Cell Cycle/drug effects | 3 | 0.0 |
Leuprolide/*pharmacology | 2 | 28.0 |
Inhibin-beta Subunits/genetics/metabolism | 2 | 100.0 |
Child, Preschool | 3 | 0.0 |
RNA, Messenger/drug effects/genetics/metabolism | 2 | 2.0 |
NIH 3T3 Cells | 2 | 0.0 |
Introns | 2 | 0.0 |
DNA-Binding Proteins/metabolism/*physiology | 5 | 4.0 |
Trans-Activators/metabolism/*physiology | 4 | 6.0 |
Epithelial Cells/drug effects/metabolism | 2 | 2.0 |
Carcinoma/*metabolism | 2 | 2.0 |
Oligonucleotides, Antisense/pharmacology | 3 | 1.0 |
Proto-Oncogene Proteins/genetics/metabolism/*physiology | 2 | 12.0 |
Transcription Factors/physiology | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Infant | 2 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Trans-Activators/biosynthesis | 2 | 5.0 |
Autocrine Communication/*physiology | 2 | 7.0 |
Cell Adhesion/*physiology | 2 | 1.0 |
Phosphoproteins/*metabolism | 3 | 0.0 |
*Membrane Proteins | 2 | 0.0 |
Activin Receptors, Type I/genetics/metabolism | 2 | 28.0 |
Collagen/metabolism | 2 | 0.0 |
Hydrophobicity | 2 | 2.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Activin Receptors, Type I/*physiology | 2 | 50.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/metabolism | 3 | 2.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Embryo/cytology | 2 | 2.0 |
Lymphocyte Activation/drug effects | 2 | 0.0 |
